Skip to main content
. 2020 May 6;128(5):057002. doi: 10.1289/EHP5444

Table 2.

Distribution of exposure and covariables of interest across participating studies.

Exposure and covariables of interest INUENDO-Greenland INUENDO-Ukraine PCB cohort HUMIS DNBC FETOTOXa INMA-Valencia INMA-Sabadell INMA-Gipuzkoa
(n=518) (n=485) (n=185) (n=989) (n=914) (n=759) (n=371) (n=378) (n=227)
Measured PFOS concentrations {ng/mL [median (range)]}a 20.19 (4.1–87.3) 5.01 (0.8–18.1) 0.03 (0.0–0.7) 0.11 (0.0–0.5) 33.55 (6.4–106.7) 26.90 (3.9–103.8) 6.20 (0.8–18.5) 6.39 (0.3–38.6) 5.30 (1.2–17.5)
Measured PFOA concentrations {ng/mL [median (range)]}b 1.83 (0.5–5.1) 0.96 (0.2–9.8) 0.03 (0.0–0.2) 0.04 (0.0–0.2) 5.26 (0.5–41.5) 4.00 (0.5–17.7) 2.39 (0.3–10.1) 2.87 (0.3–31.6) 1.66 (0.4–8.1)
Child sex (% male) 53.5 52.8 43.2 54.2 50.3 80.4 51.8 51.9 50.2
Child birth weight [kg (mean±SD)] 3,602±588 3,270±419 3,324±486 3,535±652 3,636±527 3,591±585 3,203±506 3,263±411 3,316±455
Maternal educational level (%)
 Low 56.8 60.6 46.5 8.4 2.6 4.6 26.1 23.7 10.2
 Medium 41.7 39.4 50.3 13.7 30.5 37.4 45.0 44.4 37.2
 High 1.5 0.0 3.2 77.9 66.9 58.0 28.8 31.9 52.7
Maternal age at delivery [y (mean±SD)] 27.3±6.3 25.1±4.8 26.1±4.9 30.3±4.7 30.4±4.3 29.6±4.4 31.8±4.0 31.8±4.2 33.0±3.3
Maternal prepregnancy BMI [kg/m2 (mean±SD)] 27.2±3.9 24.4±3.1 22.3±4.2 24.3±4.2 23.7±4.2 23.9±4.3 23.8±4.6 24.0±4.7 22.9±3.3
Prenatal maternal smoking (% smokers)c 87.4 31.0 17.6 7.8 20.8 28.6 39.1 26.7 22.7
Parity (% nulliparous) 31.9 80.0 36.8 37.8 45.1 47.5 57.4 59.0 55.5
Duration of total breastfeeding [months (mean±SD)] 9.3±4.1 7.7±3.9 9.8±9.8 12.4±5.2 8.0±4.7 6.7±4.8 5.3±4.4 6.4±4.5 7.0±4.6
Sample time from birth [months (mean±SD)] 3.2 ±2.7 3.7 ±2.9 0.1±0.0 1.2±0.6 7.3 ±0.5 7.0 ±1.1 6.2 ±0.4 6.0 ±0.5 6.0 ±0.5

Note: BMI, body mass index; DNBC, Danish National Birth Cohort; HUMIS, Norwegian Human Milk Study; INMA, Infancia y Medio Ambiente; PCB, polychorinated biphenyl; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonate; SD, standard deviation.

a

Observations in FETOTOX were selected using case–cohort sampling.

b

PFAS concentrations were measured in maternal serum/plasma in INUENDO-Greenland, INUENDO-Ukraine, DNBC, FETOTOX, INMA-Valencia, INMA-Sabadell, and INMA-Gipuzkoa and in breast milk in HUMIS and the PCB cohort. Specific details on chemical-analytical methods and detection/quantification limits in each study are included in Table S1.

c

In INUENDO maternal smoking was assessed prior to pregnancy.